BOARD of DIRECTORS
Henry Hsu, MD
Henry founded Allysta and serves as its CEO and President. He was a co-founder, CEO, and board member of Altheos, Inc., a private biopharmaceutical company in ophthalmic drug development. He has served as Chief Medical Officer at a number of companies, including Plexxikon, Inc., and was an early executive at CoMentis, and Molecular Therapeutics, where he had a key role in securing more than $250 million in partnerships and financings and lead the introduction of a number of new compounds in multiple INDs and across multiple indications. Previously, Henry lead drug development teams at CoTherix, InterMune, and Chiron. He received his MD from the University of California, San Francisco, and completed fellowship training at Stanford Medical Center in liver disease, where he was a Howard Hughes Physician Research Fellow.
Jason Dinges, Ph.D., J.D.
INVESTMENT ADVISOR, MORNINGSIDE TECHNOLOGY ADVISORY LLC
Jason R. Dinges, Ph.D., J.D., has served as a member of our board of directors since November 2018. Since February 2011, Dr. Dinges has served as an investment advisor at Morningside Technology Advisory LLC. Prior to that, Dr. Dinges was an associate attorney at Foley & Lardner LLP, practicing intellectual property law in the firm’s Chemical, Biotechnology and Pharmaceutical practice group. Dr. Dinges also serves on the board of directors of various privately held biotechnology companies. Dr. Dinges received his Ph.D. degree in genetics from Iowa State University and a J.D. degree from the University of Iowa College of Law.